KVISTGAARD, Denmark, April 28, 2014 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today the first patient has now been treated in a randomized, prospective Phase 2 study of its active immunotherapy candidate CV-301 in bladder cancer.
Help employers find you! Check out all the jobs and post your resume.
